Akbaş Türkay, Güneş Harun
Düzce University, School of Medicine, Düzce, Türkiye.
Balıkesir University, School of Medicine, Balıkesir, Türkiye.
J Crit Care Med (Targu Mures). 2024 Jan 30;10(1):56-63. doi: 10.2478/jccm-2024-0002. eCollection 2024 Jan.
Non-thyroidal illness syndrome (NTIS) is often observed in critically ill patients. This study aimed to examine thyroid hormone changes in patients with chronic obstructive pulmonary disease (COPD) experiencing acute hypercapnic respiratory failure (AHRF) and to evaluate the impact of these alterations on clinical outcomes.
This retrospective investigation involved 80 COPD patients (age 71.5±9.5 years; 57.5% male) admitted to the intensive care unit (ICU) due to AHRF. NTIS was identified when free triiodothyronine (fT3) levels were below the lower limit, and thyroid-stimulating hormone (TSH) and free thyroxine (fT4) levels were within the normal range or below the lower limits.
NTIS was detected in 63.7% of the patients. Decreased fT3 levels were found in 36.3% of the patients, reduced T4 levels in 33.8%, and diminished TSH levels in 15%. Patients with low fT3 levels exhibited elevated C-reactive protein levels, white blood cell counts, and APACHE II scores, necessitated vasopressor infusion more frequently during their ICU stay, and had increased mortality. The in-hospital mortality rate was 28.8%. Logistic regression analysis revealed that fT3 level (odds ratio [OR]., 0.271; 95% confidence interval [CI]., 0.085-0.865; p=0.027), APACHE II score (OR, 1.155; 95% CI, 1.041-1.282; p=0.007), and vasopressor use (OR, 5.426; 95% CI, 1.439-20.468; p=0.013) were crucial predictors of in-hospital mortality.
A high prevalence of NTIS is observed in COPD patients with AHRF, with low fT3 levels frequently observed. The presence of lower levels of fT3 is associated with a greater severity of the disease and a significant prognostic indicator.
非甲状腺疾病综合征(NTIS)在重症患者中常可见。本研究旨在检测慢性阻塞性肺疾病(COPD)急性高碳酸血症呼吸衰竭(AHRF)患者的甲状腺激素变化,并评估这些改变对临床结局的影响。
这项回顾性研究纳入了80例因AHRF入住重症监护病房(ICU)的COPD患者(年龄71.5±9.5岁;男性占57.5%)。当游离三碘甲状腺原氨酸(fT3)水平低于下限,且促甲状腺激素(TSH)和游离甲状腺素(fT4)水平在正常范围内或低于下限时,即诊断为NTIS。
63.7%的患者检测出NTIS。36.3%的患者fT3水平降低,33.8%的患者T4水平降低,15%的患者TSH水平降低。fT3水平低的患者C反应蛋白水平、白细胞计数和急性生理与慢性健康状况评分系统II(APACHE II)评分升高,在ICU住院期间更频繁地需要血管活性药物输注,且死亡率增加。住院死亡率为28.8%。逻辑回归分析显示,fT3水平(比值比[OR]为0.271;95%置信区间[CI]为0.085 - 0.865;p = 0.027)、APACHE II评分(OR为1.155;95% CI为1.041 - 1.282;p = 0.007)和血管活性药物使用(OR为5.426;95% CI为1.439 - 20.468;p = 0.013)是住院死亡率的关键预测因素。
AHRF的COPD患者中NTIS的患病率较高,且常观察到fT3水平降低。较低的fT3水平与疾病的更严重程度相关,是一个重要的预后指标。